Yazar "Yalman, D." seçeneğine göre listele
Listeleniyor 1 - 20 / 37
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Atypical and malignant meningioma: Outcome and prognostic factors in 119 irradiated patients. A multicentre, retrospective study of the rare cancer network(Pergamon-Elsevier Science Ltd, 2007) Rezvoy, N.; Bijmolt, S.; Villa, S.; Krengli, M.; Weber, D.; Baumert, B.; Canyilmaz, E.; Yalman, D.; Szutowicz, E.; Tzuk-Shina, T.Öğe Atypical and malignant meningioma: Outcome and prognostic factors in 119 irradiated patients: A multicentre, retrospective study of the rare cancer network(Elsevier Science Inc, 2007) Pasquier, D.; Bijmoli, S.; Villa, S.; Krengli, M.; Weber, D.; Baumert, B.; Canyilmaz, E.; Yalman, D.; Szutowicz, E.; Tzuk-Shina, T.Öğe Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?(Elsevier, 2021) Sert, F.; Cosgun, G.; Yalman, D.; Ozkok, S.Purpose. - To define the factors which may be related to brain metastasis (BM) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who developed brain metastases after definitive treatment. Patients and methods. - A total of 208 patients with LA-NSCLC, without BM who received definitive radiotherapy (RT) or RT + chemotherapy (CT) between January 2005 and January 2016 were evaluated retrospectively. Platelet, neutrophil, lymphocyte counts, LDH, CRP, Hb levels, neutrophil-to-lymphocyte radio (NLR), platelet-to-lymphocyte radio (PLR), advanced lung cancer inflammation index (ALI) and FDG-PET/CT parameters (SUVmax of the primary tumor and mediastinal lymph nodes), and patient characteristics were evaluated for brain metastasis free survival (BMFS). Results. - Median follow-up duration was 25 months (range: 3-130 months). Cut-off values for platelet, NLR, PLR, LDH, CRP, and Hb were 290 x 103/mu L, 2.6, 198, 468 IU/L, 2.5 mg/dL, and 11.5 g/d1. We defined each parameter as low or high according to the cut-off values. 56 patients (26.9%) developed brain metastases during follow-up. In univariate analysis, high NLR (P=0.001), PLR (P=0.037), LDH (P = 0.028), CRP (P = 0.002) values, value >= 7.5 for lymph nodes (P = 0.005) and low ALI value (P = 0.002) were poor prognostic factors for BMFS. In multivariate analysis, high NLR (P= 0.022), PLR (P= 0.017), CRP (P= 0.006), stage >= IIIB disease (P< 0.001), multi-stational N2 disease (P= 0.036), adenocarcinoma histology (P< 0.001) and SUVmax value >= 7.5 (P = 0.035) were poor prognostic factors for BMFS. Conclusions. - High NLR, PLR, LDH, CRP values, SUVmax values for lymph nodes, and low ALI which indicates high tumor burden were additional prognostic factors besides stage, histology, and lymph node status. (C) 2020 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.Öğe Clinical Outcomes for Patients with Gleason Score 10 Prostate Adenocarcinoma: TROD 09-004 Study(Elsevier Ireland Ltd, 2019) Ozyigit, G.; Onal, H. C.; Hurmuz, P.; Iribas, A.; Cetin, I.; Gorken, I. B.; Yalman, D.; Akyol, F.Öğe Comparison of Step-and-Shoot IMRT and Different Volumetric Modulated Arc Therapy (VMAT) Techniques for the Treatment of Prostate Cancer(Elsevier Science Inc, 2012) Yalman, D.; Koylu, M.; Tosun, I.; Hazeral, Y. Z.; Olacak, N.; Ozkok, S.Öğe Concurrent radiochemotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy in patients with inoperable stage III non-small cell lung cancer (NSCLC)(Elsevier Ireland Ltd, 2006) Serdar, Ozkok; Dubova, S.; Guersel, C.; Yalman, D.; T Goeksel; Goker, E.Öğe Determination of the Effect of Patient-Specific Bladder Filling Protocol for Operated Prostate Cancer Patients on Bladder Volume and Doses Using Cone Beam Computed Tomography Dose Calculations(Elsevier Science Inc, 2018) Yalman, D.; Koylu, M.; Duran, O.Öğe Development of an Intensity Modulated Total Skin Electron Irradiation Technique(Elsevier Science Inc, 2020) Koylu, M.; Kamer, S.; Anacak, Y.; Yalman, D.[No abstract available]Öğe Does a patient-specific bladder-filling protocol affect bladder volume and dose in postprostatectomy radiotherapy?(Springer Science and Business Media B.V., 2023) Yalman, D.; Köylü, M.; Duran, Ö.Purpose: Our aim is to develop a patient-specific bladder-filling protocol (PSP) using an ultrasound-based bladder scanner (BS) and compare the volumetric and dosimetric parameters with those of the standard filling protocol (SP) in postprostatectomy patients. Methods: Twenty postprostatectomy patients who received salvage radiotherapy (72 Gy/36 fx) were included. For PSP, the patient was asked to drink 500 mL of water after emptying his bladder. Bladder volume was measured using BS every 10 min. Each patient's unique time to reach a 150–200 cc volume was used for simulation and treatment. For the SP, the patient was asked about the feeling of having a full bladder. Organs at risk (OAR) were contoured on cone-beam computed tomography (CBCT) scans that were transferred to the treatment planning system (TPS). Treatment plans were applied to CBCTs. Changes in bladder volume and doses for planning computed tomography (PCT) and CBCT were determined. Results: In the SP, there was no significant difference in mean bladder volume for PCT and CBCT (p = 0.139); however, there was a trend for significance in the mean bladder dose (p = 0.074). In PSP, there was no significant difference in the mean bladder volume or dose for PCT and CBCT (p = 0.139 and p = 0.799, respectively). There was a significant difference in terms of mean CBCT bladder volume between the two protocols (p = 0.007), whereas no significant difference was detected in terms of bladder dose (p = 0.130). Conclusion: With PSP, optimal bladder filling was obtained and maintained throughout the whole treatment course, and it was reproducible in every fraction. © 2023, The Author(s), under exclusive licence to Springer Nature B.V.Öğe The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study(Elsevier Ireland Ltd, 2017) Ozyigit, G.; Onal, C.; Igdem, S.; Alicikus, Z. Arican; Iribas, A.; Akin, M.; Yalman, D.; Cetin, I.; Aksu, M. G.; Atalar, B.; Dincbas, F.; Aydin, B.; Sert, F.; Yildirim, C.; Gorken, I. B.; Agaoglu, F. Y.; Korcum, A. F.; Ozkok, S.; Darendeliler, E.; Akyol, F.Öğe Effect of Tumor Treating Fields and Radiotherapy Combination on Brain Tumor and Normal Brain Cell Lines(Elsevier Science Inc, 2020) Yalman, D.; Koylu, M.; Kayabasi, C.; Kamer, S.; Ozkan, E.; Yelken, B. Ozmen; Gunduz, C.[No abstract available]Öğe Erythropoietin and radiotherapy in lung cancer patients(Imprimatur Publications, 2009) Yurut-Caloglu, V.; Haydaroglu, A.; Ozkok, S.; Yalman, D.; Bolukbasi, Y.Purpose. To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT). Patients and methods: Thirteen consecutive patients were included. All of them had measurable tumor before RT 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 clays before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT Results: Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during R T was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034). Conclusion: rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.Öğe Evaluation of acute and late radiation morbidity in patients with gynaecologic malignancy using the RTOG criteria and Franco-Italian glossary(I R O G Canada, Inc, 2008) Yildirim, G.; Ozsaran, Z.; Yalman, D.; Kamer, S.; Aras, A.Purpose: The purpose of this study was to evaluate acute and late radiation morbidity in patients with gynaecologic malignancy using the RTOG criteria and Franco-Italian glossary, and to compare the usefulness and disadvantages of each system. Materials and Methods: Between February 2001 and February 2003, 107 patients with gynaecologic malignancy who received either radical or adjuvant external radiotherapy intracavitary brachytherapy or radiochemotherapy were enrolled in this study. The patients were evaluated before radiotherapy and weekly during radiotherapy for acute morbidity using the RTOG grading system and Franco-Italian glossary. Postradiotherapy evaluation was done one month after radiotherapy and at 3-month intervals thereafter. Median follow-up duration was 17 months. Morbidity was graded and recorded according to each scoring system. Results: Median age was 46 years (range 37-82). Sixty-four patients (59.8%) had endometrial cancer. Radical radiotherapy was applied to 26 patients because of inoperability and 81 patients received postoperative radiotherapy. Biologically effective doses for the bladder, rectum and vagina were 98.39, 103.54 and 121.81, respectively, for late morbidity (BED3); 70.88, 72.84 and 80.92, respectively, for acute morbidity (BED,,). According to the RTOG grading system acute morbidity rate for the genitourinary and gastrointestinal systems, and skin were 52.3%, 83.2% and 63.5%, respectively. Late morbidity rate for the bladder, colon-rectum, skin and vagina were 16.8%, 20.6%, 47.7% and 51.4%, respectively. The morbidity rate for the bladder, nonspecific abdominal, hematopoietic system, uterus-vulva-vagina, skin and rectum were 35.4%, 29.9%, 5.6%, 60.8%, 40.1 % and 32.7%, respectively using the Franco-Italian glossary. In patients with carcinoma of the vulva - whose treatment fields were wider - acute morbidity rate according to RTOG criteria was higher (p = 0.057); photon energy (6 My rather than 1.25 MV) (p = 0.01) and treatment interruption of more than eight days (p = 0.019) were correlated with decreased long-term morbidity. According to the Franco-Italian glossary morbidity rates were higher in patients who received chemotherapy (p = 0.047), both external radiotherapy and brachytherapy (p = 0.022) and treatment interruption of less than eight days (p = 0.019). Conclusion: There is no common language between the RTOG grading system and Franco-Italian glossary for defining and scoring radiation morbidity. Up to date no standard and well-defined system has been developed for recording and reporting acute and late radiation morbidity in gynaecologic malignancy, but rather it depends on the subjective evaluation and experience of a radiation oncologist and subjective complaints of the patient, and sometimes on clinical findings. A standard and well-defined user friendly objective scoring system is needed to define and predict the morbidity rate more properly.Öğe Evaluation of anxiety level during intracavitary brachytherapy applications in patients with gynecologic malignancy(Pergamon-Elsevier Science Ltd, 2005) Yalman, D.; Kamer, S.; Ozsaran, Z.; Celik, O.; Bolukbasi, Y.; Bildilk, O.; Haydaroglu, A.Öğe Evaluation of anxiety levels during intracavitary brachytherapy applications in women with gynecological malignancies(I R O G Canada, Inc, 2007) Kamer, S.; Ozsaran, Z.; Celik, O.; Bildik, O.; Yalman, D.; Bolukbasi, Y.; Haydaroglu, A.Purpose: To evaluate the anxiety levels of women treated for gynecological malignancies using intracavitary brachytherapy. Methods: Anxiety levels prior to and after intracavitary brachytherapy application and factors influencing anxiety levels were evaluated. Women were evaluated for quality of life and psychological status before each brachytherapy application using the Hospital Anxiety and Depression Scale (HADS). Scores were grouped as follows: 0-7 = normal, 8-10 = borderline, 11-21 = abnormal. Women were also questioned about other factors which could affect anxiety levels such as marital status, education level, number of pregnancies and prior surgical history. Results: Between January 2003 and August 2004, 146 women with a median age of 56 years were evaluated (range: 27-80). Eighty-six women had cervix uteri carcinoma and 63 had endometrial carcinoma. Sixty-seven women were premenopausal and 85 women were postmenopausal. The median pregnancy number was three (range = 0-10). Eighty-nine women had at least three children. Sixty-seven women had had previous operations. One hundred and twenty-five women were married and 24 women were unmarried or widowed. Before treatment, the anxiety scores were scored as normal in 49 (32%), borderline in 41 (28%), and abnormal in 59 (40%). Anxiety levels were lower in 69 women during the last application as compared with the pretreatment levels (p = 0.00). Marital status and pregnancy number showed a significant correlation with anxiety scores (p = 0.04). Age, level of education or having had a previous operation showed no significant correlation with anxiety level. Conclusion: These results indicate that intracavitary brachytherapy is associated with anxiety. Women need to be given detailed information before the brachytherapy application to reduce anxiety. Additional studies are needed to determine it.Öğe Geriatric Stage III NSCLC: Which scoring systems could guide us better to predict treatment outcome?(Elsevier Ireland Ltd, 2022) Sert, F.; Farzam, F.; Yalman, D.; Ozkok, S.[No Abstract Available]Öğe HPV Infection and Immunohistochemical Analysis of P16, P53, and PD-L1 Expression as Prognostic Biomarkers in Squamous Cell Anal Cancer Patients Receiving Definitive Radiotherapy/Chemoradiotherapy(Elsevier Science Inc, 2023) Topuz, B. Balcı; Sert, F.; Sezak, M.; Soylu, M.; Yalman, D.; Ozkok, S.[No abstract available]Öğe Intraluminal brachytherapy for biliary tract malignancies(Elsevier Ireland Ltd, 2006) Yalman, D.; Dubova, S.; Oezkoek, S.; Paryldar, M.; Coker, A.; Haydaroglu, A.Öğe Ipsilateral Lung Dose Constraints Predict Radiation Pneumonitis Better Than Conventional Ones in NSCLC Patients Treated with RCT(Elsevier Science Inc, 2019) Kirakli, E. Korkmaz; Erdem, S.; Erim, E.; Yalman, D.[No abstract available]Öğe Lymphopenia and accidental splenic doses for locally advanced gastric cancer(Elsevier Ireland Ltd, 2019) Sert, F.; Yalman, D.; Ozkok, S.
